金河生物(002688) - 2024年8月29日投资者关系活动记录表

Financial Performance - In the first half of 2024, the company achieved revenue of 106,574.62 million yuan, an increase of 3.22% year-on-year [1] - The net profit attributable to shareholders was 9,102.06 million yuan, up by 1.86% compared to the same period last year [1] - The net profit after deducting non-recurring gains and losses was 8,494.87 million yuan, reflecting a year-on-year increase of 2.14% [1] - The net cash flow from operating activities was 16,999.14 million yuan, a significant increase of 90.04% year-on-year [1] Segment Analysis - The veterinary chemical drug segment generated revenue of 49,929.36 million yuan, with a gross margin of 39.85%, up by 9.62 percentage points year-on-year [2] - The overseas business achieved revenue of 356 million yuan, accounting for 33% of total revenue, with the U.S. market contributing significantly [2] - The veterinary biological products segment reported revenue of 15,599.95 million yuan, a year-on-year increase of 1.68% [2] Product Development and Market Expansion - The company launched its first animal brucellosis vaccine, which has begun full-scale sales and is expected to generate significant market orders [3] - New product developments include vaccines for bovine nodular dermatitis and pseudorabies, with expected market launches in 2025 [3] - The company is expanding its pet business with six chemical products and one vaccine currently in development [4] Strategic Initiatives - The establishment of a research institute in Chengdu aims to enhance R&D capabilities and accelerate the approval process for P3 laboratory qualifications [4] - The company plans to leverage its competitive advantages in the brucellosis vaccine market, which is expected to grow significantly due to increasing demand for disease prevention [5] Future Outlook - The domestic pig farming industry is recovering, which is expected to positively impact the market for brucellosis vaccines [5] - The company anticipates that the domestic market for veterinary products will continue to grow, particularly after obtaining approval for the use of its brucellosis vaccine in ruminants [5]